AWM
UBX

Activest Wealth Management’s Unity Biotechnology UBX Stock Holding History

Activest Wealth Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200
Closed -$77 – 1196
2025
Q2 		$77 Hold
200
– – ﹤0.01% 983
2025
Q1 		$208 Hold
200
– – ﹤0.01% 934
2024
Q4 		$195 Hold
200
– – ﹤0.01% 643
2024
Q3 		$294 Hold
200
– – ﹤0.01% 505
2024
Q2 		$270 Buy
+200
New +$304 ﹤0.01% 480

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Activest Wealth Management's UBX Position: Q3 2025 in Review

Activest Wealth Management sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 200 shares — an estimated $77 sold.

Activest Wealth Management first reported a position in UBX in Q2 2024 and held it in 5 quarters. The position peaked at $294 in Q3 2024. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • Activest Wealth Management reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Activest Wealth Management sold 200 Unity Biotechnology shares in Q3 2025, an estimated $77.
  • Activest Wealth Management first reported a position in Unity Biotechnology in Q2 2024 and held it in 5 quarters.
  • Activest Wealth Management's Unity Biotechnology position peaked at $294 in Q3 2024.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on Activest Wealth Management's 13F filing for Q3 2025, filed 3 Nov 2025.